Imunon reports compliance with Nasdaq listing requirements

IMUNON announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Accordingly, IMUNON complies with all applicable listing standards, and its common stock will maintain its listing on the Nasdaq Capital Market under the symbol “IMNN.” IMUNON was notified by Nasdaq on December 26, 2023 that it was not in compliance with the Minimum Bid Price Requirement because its common stock had failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. To regain compliance with the Rule, the Company’s common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on April 9, 2024, the 10th consecutive trading day when the closing bid price of the Company’s common stock was over $1.00.